Neflamapimod

N/A

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameNeflamapimod
Drug Alias NameVX-745
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 mitogen-activated protein kinase inhibitors
TargetsP38 mitogen-activated protein kinase
Therapy Area/IndicationsIschemic StrokeCognitive DysfunctionPrimary Progressive Nonfluent Aphasia +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesNetherlands +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesCervoMed IncToulouse University HospitalEip Pharma Inc
Inactive CompaniesN/A
Active IndicationsIschemic StrokePrimary Progressive Nonfluent AphasiaAlzheimer Disease +[4] 
Inactive IndicationsCognitive DysfunctionHuntington Disease

Other Information

ATC CodeN/A
Related LinksN/A